Zachary Silbersher, et al v. Valeant Pharmaceuticals Int'l, et al
Case Number:
20-16176
Court:
Nature of Suit:
Companies
- Adamas Pharmaceuticals Inc.
- Bausch Health Cos. Inc.
- BTG International Inc.
- BTG PLC
- Johnson & Johnson
- Salix Pharmaceuticals, Ltd.
- Taxpayers Against Fraud Education Fund
Government Agencies
Sectors & Industries:
-
January 05, 2024
9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend its monopoly on the drug Apriso.
-
September 19, 2023
Valeant Says 9th Circ.'s FCA Disclosure Ruling Went Too Far
The drugmaker behind a major bowel disease treatment said that a Ninth Circuit panel split with "at least eleven" other appeals courts when it ruled that putting together disclosures from patent proceedings could underpin a patent lawyer's use of whistleblower laws to go after the pharmaceutical company over claims of fraud.
-
August 03, 2023
9th Circ. Revives Atty's FCA Suit Against Valeant Over Apriso
The Ninth Circuit on Thursday revived a False Claims Act suit accusing Valeant Pharmaceuticals of fraudulently obtaining a patent to prolong its monopoly on its drug Apriso, finding the statute's public disclosure bar doesn't block the suit since disclosures from patent proceedings and prior news coverage don't say Valeant committed fraud.
-
June 10, 2022
9th Circ. Mulls If Valid Patents Moot FCA Suit Against Bausch
A Ninth Circuit judge considering whistleblower allegations that Bausch Health fraudulently obtained a patent to prolong its monopoly on colitis drug Apriso pressed the plaintiff's attorney Friday on whether other valid patents also protected the drug, commenting, "If that's the case, then you don't have a False Claims Act claim."